From water to aquaretics: A legendary route

Cellular Physiology and Biochemistry

Volumn 33, Issue 5, 2014, Pages 1369-1388

  Donato, Valentina ^a   Lacquaniti, Antonio ^a   Cernaro, Valeria ^a   Lorenzano, Giuseppina ^a   Trimboli, Domenico ^a   Buemi, Antoine ^a   Lupica, Rosaria ^a   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Aquaretics; Osmolarity; Vasopressin

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; APELIN; AQUAPORIN; VASOPRESSIN; WATER; AMILORIDE; APELIN RECEPTOR; AQUAPORIN 1; AQUAPORIN 2; ARGIPRESSIN; CONIVAPTAN; CYCLOOXYGENASE 2 INHIBITOR; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LITHIUM SALT; LIXIVAPTAN; MILRINONE; POTASSIUM; RELCOVAPTAN; ROLIPRAM 8; ROLIPRAM DERIVATIVE; SILDENAFIL; SODIUM; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 4; VASOPRESSIN RECEPTOR;

ARTICLE; BLOOD PRESSURE; BLOOD VOLUME; HOMEOSTASIS; HUMAN; NONHUMAN; OSMOLARITY; OSMOREGULATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WATER ABSORPTION; WATER TRANSPORT; AUTOMATION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; DENDRITE; ELECTRICITY; GENE LOCUS; HEART MUSCLE CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INOTROPISM; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; NERVE FIBER; NEUROHYPOPHYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SODIUM BLOOD LEVEL; VASODILATATION; ANIMAL; METABOLISM;

VERTEBRATA;

ANIMALS; AQUAPORINS; HOMEOSTASIS; HUMANS; OSMOREGULATION; RENIN-ANGIOTENSIN SYSTEM; WATER;

EID: 84900900740     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358704     Document Type: Article

References (56)

1. Corvol P, Elghozi JL: Sortir De l'eau. Paris,Editions Odile Jacob, 2011, pp 1-240.
2. Noble D: Claude Bernard, the first systems biologist, and the future of physiology. Exp Physiol 2008;93:16-26. (Pubitemid 350293978)
3. Mariotti M: Marine serum, concept of its inventor, Rene Quinton; possibility of its application today. Minerva Med 1952;43:777-779.
4. Cannon WB: Pharmacological injections and physiological inferences. Science 1929;70:500-501.
5. Thornton SN: Thirst and hydration: Physio logy and consequences of dysfunction. Physiol Behav 2010;26:100:515-21.
6. Lorens-Cortes C, Moos F: Opposite potentiality of hypothalamic coexpressed neuropeptides,apelin and vasopressin in maintaining body-fluid homeostasis. Prog Brain Res 2008;170:559-570. (Pubitemid 352010251)
7. Bourque CW Central mechanisms of osmosensation and systemic osmoregulation Nat Rev Neurosci 2008 9 519-531. (Pubitemid 351873462)
8. Lechner SG, Markworth S, Poole K, Smith ES, Lapatsina L, Frahm S: The molecular and cellular identity of peripheral osmoreceptors. Neuron 2011;69:332-344.
9. Ciura S, Liedtke W, Bourque CW: Hypertonicity sens ing in organum vasculosum lamina terminalis neurons: A mechanical process involving TRPV1 but not TRPV4. J Neurosci 2011;31:14669-14676.
10. Laragh JH: Renin angiotensin aldosterone system for blood pressure and elect rolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens 1995;9:385-390.
11. Tracy RE: Renal vascul ature in essential hypertension: A review of some contrarian evidence Contrib Nephrology 2011;169:327-336.
12. Shestakova MV: [Renin-angiotensin-aldosteron system: Evolution of views from renin discovery to nowadays. Perspectives of therapeutic block]. Ter Arkh 2011;71-77.
13. Zhang Z, Bourque CW: Bourque Amplification of Transducer Gain by Angiotensin II Mediated Enhancement of Cortical Actin Density in Osmosensory Neurons. J Neurosci 2008;9536-9544.
14. Treschan TA, Peters J: The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006;105:599-612. (Pubitemid 44310444)
15. Pequeux C, Keegan BP, Hagelstein MT, Ge enen V, Legros JJ, North WG: Oxytocin-and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer 2004;11:871-885. (Pubitemid 40065559)
16. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephr ol 1999;10:20165-20170.
17. Bu emi M, Corica F, Di Pasquale G, Aloisi C, Sofi M, Casuscelli T, Floccari F, Senatore M, Corsonello A, Frisina N: Water immersion increases urinary excretion of aquaporin-2 in healthy humans. Nephron 2000;85:1:20-26. (Pubitemid 30242825)
18. Buemi M, Di Pasquale G, Ruello A, Floccari F, Aloisi C, Latassa G, Corsonello A, Sturiale A, Corica F, Frisina N: Effect of a prostacyclin analogue, iloprost, on urinary aq uaporin-2 excretion in humans. Nephron 2002;91:197-202. (Pubitemid 34621683)
19. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ: Distribution of mRNA encoding B78/apj, therat homologue of the human APJ receptor, and its endogen ous ligand apelin in brain and peripheraltissues. Biochim Biophys Acta 2000;21;72-80. (Pubitemid 30349182)
20. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG: Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003;84:1162-1172. (Pubitemid 36330668)
21. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M: Isolation and characterization of a novel endogenous peptide ligand for the hum an APJ receptor. Biochem Biophys Res Commun 1998;251:471-476. (Pubitemid 28505047)
22. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP: Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev 2010;62:331-342.
23. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T: A human gene that shows identity with the gene encoding the angioten sin receptor is located on chromosome 11. Gene 1993;136:355-360. (Pubitemid 24049270)
24. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, Fujino M: Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999;1452:25-35. (Pubitemid 29486739)
25. Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP: [Pyr1]apelin-13 identified as the prominent apelin isoform in the human heart: Vasoactive mechanism and inotropic action in disease. Hypertension 2009;54: 598604.
26. Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C: Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 2002;113:653-662. (Pubitemid 34874689)
27. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L: Diabetesinduced albuminuria: Role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrololy Dialysis Transplant 2003;18:1755-1763. (Pubitemid 37098545)
28. Herrera VL Ruiz-Opazo N Identification of a novel V1-type AVP receptor based on the molecular recognition theory Mol Med 2001 7 499-506. (Pubitemid 33701971)
29. Thompson AM, Oliver JA: Endogenous and exogenous vasopressin during hemodialysis. Semin Dial 2009;22:472-475.
30. Rho M, Perazella MA, Parikh CR, Peixoto AJ, Brewster UC: Serum vasopressin response in patient with intradialytic hypotension: A pilot study. Clin J Am Soc Nephrol 2008;3:729-735.
31. Shimizu K, Kurosawa T, Sanjo T: Effect of hyperosmolality on vasopressin secretion in intradialytic hypotension: A mechanistic study. Am J Kidney Dis 2008;52:294-304. (Pubitemid 351978136)
32. Cernaro V, Lacquaniti A, Lorenzano G, Loddo S, Romeo A, Donato V, Lupica R, Buemi A, Buemi M: Apelin, plasmatic osmolality and hypotension in dialyzed patients. Blood Purif 2012;334:317-323.
33. El-Shehaby AM, E l-Khatib MM, Battah AA, Roshdy AR: Apelin: A potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010;70:421-427.
34. Kalea AZ, Batll e D: Apelin and ACE2 in cardiovascular disease. Curr Opin Investig Drugs 2010;11:273-282.
35. Zhong JChang, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG: Apelin modulates aortic vascular tone via e ndothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007;74:388-395. (Pubitemid 46693698)
36. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M: The novel peptide apelin lowers blood pressure via a nitric oxide-dipendent mechanism. Regul Pept 2001;99:87-92. (Pubitemid 32522535)
37. Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, Soubrier F: Hypoxia-Induced Apelin Expression Regulates Endothelial Cell Proliferation and Regenerative Angiogenesis. Circ Res 2008:103:432-440.
38. Kidoya H, Takakura N: Biology of the apelin-APJ axis in vascular formation. J Biochem 2012;152:125-131.
39. Japp AG, Cruden NL, Amer DA, L VK, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE: Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008;52:908-913.
40. Agre P, Nielsen S: The aquaporin family of water channels in kidney. Nephrologie 1996;17:409-415. (Pubitemid 26413081)
41. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frpkiaer J, Marples D: Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999;10:647-663. (Pubitemid 29117647)
42. Kwon TH, Nielsen J, Mpller HB, Fenton RA, Nielsen S, Frpkiaer J: Aquaporins in the kidney.Handb Exp Pharmacol 2009;95-132.
43. Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E: Regulation of aquaporin-2 trafficking.Handb Exp Pharmacol 2009;133-157.
44. Cheng CY, Chu JY, Chow BK: Vasopressin-independent mechanisms in controlling water homeostasis. J Mol Endocrinol 2009;43:81-92.
45. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominantpolycystic kidney disease. Nat Med 2004;10:363-364. (Pubitemid 38508512)
46. Danov itch GM, Le Roith D, Glick S: Renal function during treatmentof inappropriate secretion of antidiuretic hormone with demeclocycline. Isr J Med Science 1978;14:852-857.
47. Miller PD, Linas SL, Schrier R W: Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-2515. (Pubitemid 10039244)
48. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New Engl J Med 2006;355:2099-2112. (Pubitemid 44749318)
49. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr: Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in humanheart failure. Am J Physiol Renal Physiol 2006;290:2 73-238.
50. Hirano T Yamamura Y Nakamura S Onogawa T Mori T Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 2000;292; 288-294. (Pubitemid 30026383)
51. Weinberger MH: Diuretics and their side effects. Dilemma in the treatment of hypertension. Hypertension 1988;11:16-20.
52. Bellizzi V, Scalfi L, Terracciano V, De Nico La L, Minutolo R, Marra M, Guida B, Cianciaruso B, Conte G, Di Iorio BR: Early changes in bioelectrical estimates of body composition in chronic kidney disease. J Am Soc Nephrol 2006;17:1481-1487. (Pubitemid 43673431)
53. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L: Diabetes induced albuminuria: Role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003;18:1755-1763 . (Pubitemid 37098545)
54. Lacheretz F, Barbier A, Serradeil-Le Gal C, Elena PP, Maffrand JP,Le Fur G: Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular. J Ocul Pharmacol Ther 2 000;16:203-216. (Pubitemid 30366282)
55. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA: Rationale and design of the multicenter , randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism inHeart Failure: Outcome Study with Tolvaptan (EVEREST). J CardFail 2005;11:260-269. (Pubitemid 40626781)
56. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E,Perrone RD, Krasa HB, Ouyang J, Czerwiec FS: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-2418.